WEE1 and cancer: Due to the continuous resistance development by cancer cells on one hand and the more satisfactory effect and less drawbacks achieved by the concurrent targeting of multiple protein kinases on the other hand [47, 48], there is a continuous demand for developing small molecules that target more than one protein kinase simultaneously (multi-kinase inhibitors).